首页> 外文期刊>Contraception >Observational study of the acceptability of Sayana? Press among intramuscular DMPA users in Uganda and Senegal
【24h】

Observational study of the acceptability of Sayana? Press among intramuscular DMPA users in Uganda and Senegal

机译:观察Sayana的可接受性研究? 在乌干达和塞内加尔的肌内DMPA用户中的媒体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background Sayana? Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject?, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among DMPA IM users. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based distribution services in two districts in Uganda. Experienced DMPA IM users were offered SP by community health workers (CHWs) or clinic-based providers. SP decliners were asked to discuss their reasons. Those who received SP were interviewed pre- and postinjection and 3 months later, when they were asked if they would select SP over DMPA IM if it were available. Results One hundred twenty women in Uganda and 242 in Senegal received SP (117 and 240 were followed up, respectively). Nine Ugandan and seven Senegalese SP decliners were interviewed. Three months after receiving SP, 84% [95% confidence interval (CI)=75%-93%] of Ugandan participants and 80% (95% CI=74%-87%) of Senegalese participants said they would select SP over DMPA IM. Main reasons for selecting SP were fewer side effects, liking the method, fast administration, less pain and method effectiveness. Thirty-four adverse events were reported but were not serious. No pregnancies were reported. Conclusion Current DMPA IM users in Senegal and Uganda accepted SP, and most preferred SP over DMPA IM. SP can be safely introduced into FP programs and administered by trained CHWs, with expectation of client uptake. Implications We found SP acceptable and safe in diverse settings among current intramuscular DMPA users, including those who received SP from CHWs. This provides evidence that SP would be used and could therefore reduce unmet family planning needs if introduced into family planning programs.
机译:背景Sayana?按(SP),在UNIJE11中的Depot Medroxypergerone乙酸盐(DMPA)的皮下制剂有可能成为计划生育(FP)的有价值的创新,因为它可能会克服肌肉内DMPA(DMPA IM)来克服物流和安全挑战。但是,SP的可接受性是未知的。我们在DMPA IM用户中测量了SP的可接受性。研究设计这项开放标签观察研究是在塞内加尔的三个地区的诊所进行的,在乌干达的两个地区进行了三个地区。经验丰富的DMPA IM用户由社区卫生工作者(CHW)或基于诊所的提供商提供SP。 SP拒绝者被要求讨论其原因。那些收到SP的人在被问及和发布之前,3个月后,当他们被问到他们是否会在DMPA上选择SP,如果它可以使用。结果乌干达有一百二十名妇女在塞内加尔接收到SP(117和240,分别跟进)。接受了九乌干达和七个塞内加尔SP颓废者。收到SP后三个月,84%[95%置信区间(CI)= 75%-93%]乌干达参与者和80%(95%CI = 74%-87%)塞内加尔参与者表示,他们将选择SP Over DMPA我是。选择SP的主要原因是较少的副作用,喜欢该方法,快速管理,较少的疼痛和方法有效性。报告了三十四所不良事件,但并不严重。没有报告怀孕。结论当前DMPA IM用户在塞内加尔和乌干达接受SP,最优选的SP OVER DMPA IM。可以安全地将SP安全引入FP程序并由培训的CHWS进行管理,期望客户吸收。含义我们在当前肌肉内DMPA用户之间的不同环境中找到了SP可接受和安全的,包括从CHWS接收SP的人。这提供了证据,即SP将被使用,因此可以减少在计划生育计划中的情况下减少未满足的计划生育需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号